Stock Market Update - March 18, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. SWMR - Swarmer, Inc Common Stock
Price: $55 | Change: +77.42% ($24)
SWMR:NASDAQ just posted a significant 77.42% gain, building on an explosive debut following its Initial Public Offering (IPO) on March 17, 2026. Shares of Swarmer, Inc., a Ukrainian defense-technology company, initially priced at $5.00, saw investor demand skyrocket, leading to a remarkable nearly 1,100% increase over its first two days of trading.
This extraordinary movement is fueled by Swarmer's core business: developing advanced software that allows groups of drones to coordinate autonomous actions. This technology isn't just theoretical; it has been battle-tested in Ukraine since 2023/2024, completing over 100,000 combat missions and providing strong real-world validation. The IPO, which raised $15 million, aligns with heightened global demand for defense technology and autonomous drone systems amid ongoing geopolitical conflicts, also marking a historic moment as the first Ukrainian defense tech company to go public on Nasdaq.
2. ARTL - Artelo Biosciences, Inc.
Price: $7.31 | Change: +50.72% ($2.46)
Artelo Biosciences (ARTL:NASDAQ) recently saw an impressive 50.72% gain. The biotech company's stock jumped after announcing its strategic entry into the ophthalmology space with a fully funded clinical study for its drug, ART27.13, aimed at treating glaucoma and ocular hypertension.
What made this news particularly impactful was the trial's funding. It's backed by Glaucoma UK and the HSC R&D Division, meaning Artelo can diversify its pipeline into a new area without having to issue new shares and dilute existing shareholders.
This non-dilutive funding mechanism for a new clinical development, targeting the substantial global glaucoma market (projected to reach over $16 billion by 2033), was a key factor behind the positive market reaction and a new growth avenue for the company.
3. HSPTU - Horizon Space Acquisition II Corp.
Price: $10.44 | Change: +44.20% ($3.2)
HSPTU recently experienced a notable uptick, soaring 44.20%. This significant move for Horizon Space Acquisition II Corp., a special purpose acquisition company (SPAC), was primarily driven by its continued progress toward a business combination with SL BIO Ltd. The catalyst for the surge was the announcement that HSPTU extended its deadline to complete this merger by one month, moving it to April 18, 2026.
This extension wasn't just a simple date change; it was facilitated by a $50,000 promissory note from William Wang, the CEO of SL BIO Ltd., which was deposited into the SPAC's trust account for public shareholders. This ongoing insider financing and the extended timeline appear to have reassured investors that the merger, initially announced in May 2025, remains firmly on track, reducing the risk of the SPAC liquidating without completing a deal.
4. AIM - AIM ImmunoTech Inc.
Price: $1.02 | Change: +43.66% ($0.31)
AIM:AMEX recently saw its stock surge by a notable 43.66%, driven by a significant regulatory win. Around March 19, 2026, AIM ImmunoTech announced the final approval of a key patent in Japan for its experimental cancer therapy, Ampligen (rintatolimod). This patent specifically covers the use of Ampligen in combination with checkpoint inhibitors for various cancer treatments.
This wasn't just any patent; it successfully completed a mandatory six-month opposition period, securing intellectual property protection in Japan until December 20, 2039. Japan represents one of the largest global pharmaceutical markets, making this a particularly impactful milestone. The broad patent includes coverage for difficult-to-treat diseases like pancreatic cancer, and the company intends to pursue "orphan drug" designation for Ampligen in Japan for this condition, building on similar statuses in the U.S. and Europe.
5. ZYBT - Zhengye Biotechnology Holding Limited
Price: $0.9799 | Change: +36.10% ($0.2599)
ZYBT recently saw its stock price jump by an impressive 36.10%, largely attributed to the release of an optimistic Chairman's Letter to Shareholders in early March 2026.
The letter highlighted Zhengye Biotechnology's strong performance in 2025, detailing new patent grants, several key veterinary drug approvals in China, and a successful expansion of its vaccine product portfolio into international markets. For 2026, the company laid out an ambitious strategic vision, including plans to deepen customer engagement, strengthen its product lineup, and strategically expand into the growing companion animal sector.
Investors reacted positively to this combination of tangible past achievements and a clear, forward-looking strategy. What particularly garnered attention was the company's intent to leverage the anticipated recovery in China's swine market by mid-2026, alongside its entry into new animal health segments, painting a promising picture for the future.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.